Accessibility Menu
Theralink Technologies logo

Theralink Technologies(OTC) THER

Market Cap$6.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
Theralink Technologies last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-07
Theralink Technologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-16
1 month+0%USD 0.002026-06-01
3 month+0%USD 0.002026-04-28
Year to date+0%USD 0.002025-12-31
1 year+0%USD 0.002025-07-28
3 year-99.93%USD 0.002023-08-08
5 year-100%USD 0.422021-08-06
Since inception-100%USD 337.512015-09-11

Theralink Technologies Financials at a Glance

Market Cap

$6.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$753.95K

Net Income (TTM)

-$1.26M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-0.71 (Low)

Price

$0.00

Volume

10

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Feb 24, 2025

THER News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Theralink Technologies

Theralink Technologies, Inc. is a commercial-stage biotechnology company based in Golden, Colorado, specializing in precision medicine and molecular data generation. The company focuses on advancing innovative cancer immunotherapy products through its proprietary platform, which emphasizes phosphoprotein and protein biomarkers.

Products and Services
  • Proprietary Theralink Reverse Phase Protein Array assays for oncology data
  • Laboratory-developed tests (LDT) for predicting patient responses to treatments
  • Diagnostic assays providing actionable insights for physicians and biopharmaceutical companies
Growth Outlook
  • Recent quarterly revenue of $179,267 shows potential for growth
  • Gross profit margin improved to 77.7% in Q4 2023
  • Continued focus on precision medicine positions the company for future expansion
Financial Highlights
  • Net income of $9,615,175 reported in Q4 2023
  • Operating expenses increased to $2,474,957 in Q4 2023
  • Cash and cash equivalents reached $997,484 as of September 30, 2023
Theralink Technologies, Inc. operates in a dynamic sector, leveraging advanced technologies to provide critical insights in cancer treatment. The company's focus on precision medicine and innovative diagnostic solutions positions it well within the biotechnology industry. Recent financial performance indicates a potential for growth, particularly with a notable increase in gross profit margins. The company’s ability to generate significant net income in the latest quarter reflects its operational capabilities and market potential. As the demand for personalized medicine continues to rise, Theralink's offerings may become increasingly relevant, making it an intriguing option for investors interested in the biotechnology space.
AI Generated • Jul 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

16

CEO

Faith Zaslavsky

Website

www.theralink.com

Headquarters

Golden, CO 80401, US

THER Financials

Key Financial Metrics (TTM)

Gross Margin

79.20%

Operating Margin

-1479.80%

Net Income Margin

-5093.56%

Return on Equity

147.47%

Return on Capital

N/A

Return on Assets

-1084.55%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

-0.09%

Stock Overview

Market Cap

$6.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

6.15B

Volume

10

Avg. Volume

27.48K

Financials (TTM)

Gross Profit

$588.45K

Operating Income

-$8.33M

EBITDA

-$7.84M

Operating Cash Flow

-$4.75M

Capital Expenditure

-$163.38K

Free Cash Flow

-$4.91M

Cash & ST Invst.

$998.28K

Total Debt

$19.76M

Theralink Technologies Performance Analysis

Theralink Technologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-09-30USD 505,604N/A
20222022-09-30USD 567,90512.3%
20232023-09-30USD 606,7966.8%
Theralink Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-12-31-44.4%
Q22023-03-3119.2%
Q32023-06-30N/A
Q42023-09-30-11.4%
Theralink Technologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-09-30USD -0.00N/A
20222022-09-30USD -0.0083.3%
20232023-09-30USD -0.01127.3%
Theralink Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-12-31-146.2%
Q22023-03-31106.3%
Q32023-06-30N/A
Q42023-09-30700.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2023YOY CHG

Revenue

$179.27K

-41.3%

Gross Profit

$139.36K

-42.1%

Gross Margin

77.74%

N/A

Market Cap

$6.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$387.50

N/A

Employees

16

N/A

Net Income

$9.62M

+225.1%

EBITDA

-$2.48M

-5357.6%

Quarterly Fundamentals

Name
Q4 2023YOY CHG

Total Cash

$998.28K

+151.4%

Total Debt

$19.76M

+351.7%

Accounts Receivable

$23.91K

-25.6%

Inventory

$0.00

N/A

Long Term Debt

$1.13M

-61.6%

Short Term Debt

$18.63M

+1202.4%

Return on Assets

-10.85%

N/A

Return on Invested Capital

24.28%

N/A

Free Cash Flow

-$1.66M

-70.6%

Operating Cash Flow

-$1.50M

-61.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NSHSFNanoSphere Health Sciences Inc.
$0.01+0.00%
BZYRBurzynski Research Institute, Inc.
$0.01+0.00%
BIXTBioxytran, Inc.
$0.02-15.66%
BVAXFBioVaxys Technology Corp.
$0.08+18.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About THER

What is the current price of Theralink Technologies?

Theralink Technologies is trading at $0.00 per share.

What is the 52-week range for Theralink Technologies?

Over the past 52 weeks, Theralink Technologies has traded between $0.00 and $0.00.

How much debt does Theralink Technologies have?

As of the most recent reporting period, Theralink Technologies reported total debt of $19.76M.

How much cash does Theralink Technologies have on hand?

Theralink Technologies reported $997.48K in cash and cash equivalents in its most recent financial results.

What is Theralink Technologies’s dividend yield?

Theralink Technologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services